首页> 外文期刊>Molecular vision >Effects of N-acetylcysteine and glutathione ethyl ester drops on streptozotocin-induced diabetic cataract in rats
【24h】

Effects of N-acetylcysteine and glutathione ethyl ester drops on streptozotocin-induced diabetic cataract in rats

机译:N-乙酰半胱氨酸和谷胱甘肽乙酯滴剂对链脲佐菌素诱发的糖尿病性白内障的影响

获取原文
获取外文期刊封面目录资料

摘要

Purpose: To evaluate the effect ofN-acetylcysteine (NAC) and glutathione ethyl ester (GSH-EE) eye dropson the progression of diabetic cataract formation induced bystreptozotocin (STZ). Methods: One hundred and thirtySprague-Dawley (SD) rats were selected, and diabetes was induced bystreptozotocin (65 mg/kg bodyweight) in a single intraperitonealinjection. The control group (group I) received only vehicle. Then, 78rats with random blood glucose above 14 mmol/l were divided into fourgroups (group II-V). The drug-treated rats received NAC and GSH-EE eyedrops five days before STZ injection. Group I and V animals receivedsodium phosphate buffer drops (pH 7.4), and those in groups II, III,and IV received 0.01% NAC, 0.05% NAC, and 0.1% GSH-EE drops,respectively. Lens transparency was monitored with a slit lampbiomicroscope and classified into six stages. At the end of four weeks,eight weeks, and 13 weeks, animals were killed and components involvedin the pathogenesis of diabetic cataract including thiols (fromglutathione and protein), glutathione reductase (GR), catalase (CAT),and glycated proteins were investigated in the lens extracts. Bloodglucose, urine glucose, and bodyweight were also determined. Results: The progression in lens opacityinduced by diabetes showed a biphasic pattern in which an initial slowincrease in the first seven weeks after STZ injection was followed by arapid increase in the next six weeks. The progression of lens opacityin the treated groups (group II-IV) was slower than that of theuntreated group (group V) in the earlier period and especially in thefourth week. There were statistically significant differences betweenthe treated groups and the untreated group (p0.05). However, thesedifferences became insignificant after the sixth week, and theprogression of lens opacification in all diabetic groups becameaggravated. The content of thiol (from glutathione and protein),glutathione reductase (GR), and catalase (CAT) were lower in the lensextracts of the diabetic rats four weeks, eight weeks, and 13 weeksafter the STZ injection while the levels of thiol and CAT activity wereboth higher in the treated groups (group II-IV) than in the untreatedgroup (group V) at every stage. However, there was no statisticallysignificant difference (p0.05). Moreover, the diabetes resulted inan increased level of glycated proteins in both the treated groups andthe untreated group, but there was no statistically significantdifference between all the diabetic groups (p0.05). Conclusions: NAC and GSH-EE can slightlyinhibit the progression of the diabetic cataract at the earlier stage.They may maintain lens transparency and function by serving as aprecursor for glutathione biosynthesis and by protecting sulfhydrylgroups from oxidation.
机译:目的:评估N-乙酰半胱氨酸(NAC)和谷胱甘肽乙酯(GSH-EE)眼药水对链脲佐菌素(STZ)诱导的糖尿病性白内障形成的影响。方法:选择一百三十只SD大鼠,并通过一次腹膜内注射链脲佐菌素(体重65 mg / kg)诱导糖尿病。对照组(I组)仅接受车辆。然后,将随机血糖高于14 mmol / l的78只大鼠分为四组(II-V组)。药物治疗的大鼠在STZ注射前五天接受了NAC和GSH-EE滴眼液。 I组和V组动物分别接受磷酸钠缓冲液滴(pH 7.4),II,III和IV组动物分别接受0.01%NAC,0.05%NAC和0.1%GSH-EE滴剂。用裂隙灯生物显微镜监测镜片的透明度,并分为六个阶段。在第4周,第8周和第13周结束时,杀死了动物,并研究了糖尿病白内障的发病机制,包括硫醇(来自谷胱甘肽和蛋白质),谷胱甘肽还原酶(GR),过氧化氢酶(CAT)和糖化蛋白质。镜片提取物。还测定了血糖,尿糖和体重。结果:糖尿病引起的晶状体混浊的进展呈双相型,其中STZ注射后最初的7周开始缓慢增加,随后的6周迅速增加。在较早的时期,特别是在第4周,治疗组(II-IV组)的晶状体混浊的进展慢于未治疗组(V组)。在治疗组和未治疗组之间存在统计学上的显着差异(p <0.05)。然而,第六周后这些差异变得微不足道,并且所有糖尿病组中晶状体混浊的进展都加重了。 STZ注射后4周,8周和13周,糖尿病大鼠晶状体提取物中的巯基含量(来自谷胱甘肽和蛋白质),谷胱甘肽还原酶(GR)和过氧化氢酶(CAT)较低,而巯基和CAT的含量较低在每个阶段,治疗组(II-IV组)的活性均高于未治疗组(V组)。但是,差异无统计学意义(p> 0.05)。此外,糖尿病导致治疗组和未治疗组糖化蛋白水平升高,但所有糖尿病组之间均无统计学差异(p> 0.05)。结论:NAC和GSH-EE可以在早期阶段轻微抑制糖尿病性白内障的进展,它们可以作为谷胱甘肽生物合成的前体并保护巯基免受氧化而保持晶状体透明性和功能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号